ZA200609337B - Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin - Google Patents
Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurinInfo
- Publication number
- ZA200609337B ZA200609337B ZA200609337A ZA200609337A ZA200609337B ZA 200609337 B ZA200609337 B ZA 200609337B ZA 200609337 A ZA200609337 A ZA 200609337A ZA 200609337 A ZA200609337 A ZA 200609337A ZA 200609337 B ZA200609337 B ZA 200609337B
- Authority
- ZA
- South Africa
- Prior art keywords
- prevention
- treatment
- diseases associated
- opioid antagonist
- antagonist compounds
- Prior art date
Links
- 102000004631 Calcineurin Human genes 0.000 title abstract 2
- 108010042955 Calcineurin Proteins 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003401 opiate antagonist Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003809 morphinane derivatives Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04011293A EP1595541A1 (en) | 2004-05-12 | 2004-05-12 | Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200609337B true ZA200609337B (en) | 2008-08-27 |
Family
ID=34924978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200609337A ZA200609337B (en) | 2004-05-12 | 2006-11-09 | Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070167474A1 (xx) |
EP (2) | EP1595541A1 (xx) |
JP (2) | JP2007537198A (xx) |
CN (1) | CN1997369B (xx) |
AT (1) | ATE445401T1 (xx) |
AU (1) | AU2005239831A1 (xx) |
CA (1) | CA2566398A1 (xx) |
DE (1) | DE602005017145D1 (xx) |
ES (1) | ES2334042T3 (xx) |
MX (1) | MXPA06013128A (xx) |
NO (1) | NO20065551L (xx) |
RU (1) | RU2006143770A (xx) |
WO (1) | WO2005107752A2 (xx) |
ZA (1) | ZA200609337B (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009233315B2 (en) | 2008-03-31 | 2013-08-29 | Sun Pharmaceutical Industries Ltd. | An improved process for the preparation of morphinane analogues |
WO2009132313A2 (en) * | 2008-04-25 | 2009-10-29 | Progenics Pharmaceuticals, Inc. | Morphinan derivatives of organic and inorganic acids |
WO2011009020A2 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
EP2641588B1 (en) | 2012-03-23 | 2017-11-22 | Induchem Holding AG | Use of agonists of delta opioid receptor in cosmetic and dermocosmetic field |
KR101694879B1 (ko) * | 2014-08-01 | 2017-01-12 | 주식회사 인트론바이오테크놀로지 | 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도 |
AU2015321470B2 (en) * | 2014-09-22 | 2018-11-15 | National Health Research Institutes | Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases |
WO2020012248A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Novel naphthylenyl compounds for long-acting injectable compositions and related methods |
WO2020012245A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Thienothiophene-naltrexone prodrugs for long-acting injectable compositions |
WO2020094634A1 (en) | 2018-11-05 | 2020-05-14 | Alkermes Pharma Ireland Limited | Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007896A1 (en) | 1992-09-29 | 1994-04-14 | Toray Industries, Inc. | Indole derivative, process for producing the same, and medicinal use thereof |
SE9401728D0 (sv) * | 1994-05-18 | 1994-05-18 | Astra Ab | New compounds II |
US6825203B2 (en) * | 2000-04-28 | 2004-11-30 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
ES2572332T3 (es) | 2000-10-31 | 2016-05-31 | Rensselaer Polytech Inst | 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides |
WO2004026819A2 (en) | 2002-09-18 | 2004-04-01 | The Curators Of The University Of Missouri | OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR |
-
2004
- 2004-05-12 EP EP04011293A patent/EP1595541A1/en not_active Withdrawn
-
2005
- 2005-05-12 CA CA002566398A patent/CA2566398A1/en not_active Abandoned
- 2005-05-12 AU AU2005239831A patent/AU2005239831A1/en not_active Abandoned
- 2005-05-12 CN CN2005800181491A patent/CN1997369B/zh not_active Expired - Fee Related
- 2005-05-12 ES ES05742958T patent/ES2334042T3/es active Active
- 2005-05-12 RU RU2006143770/04A patent/RU2006143770A/ru not_active Application Discontinuation
- 2005-05-12 US US11/579,900 patent/US20070167474A1/en not_active Abandoned
- 2005-05-12 JP JP2007512104A patent/JP2007537198A/ja active Pending
- 2005-05-12 MX MXPA06013128A patent/MXPA06013128A/es not_active Application Discontinuation
- 2005-05-12 DE DE602005017145T patent/DE602005017145D1/de active Active
- 2005-05-12 AT AT05742958T patent/ATE445401T1/de active
- 2005-05-12 WO PCT/EP2005/005176 patent/WO2005107752A2/en active Application Filing
- 2005-05-12 EP EP05742958A patent/EP1755604B1/en active Active
-
2006
- 2006-11-09 ZA ZA200609337A patent/ZA200609337B/xx unknown
- 2006-12-01 NO NO20065551A patent/NO20065551L/no not_active Application Discontinuation
-
2012
- 2012-06-28 JP JP2012145951A patent/JP2012254986A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2005107752A3 (en) | 2006-06-01 |
EP1595541A1 (en) | 2005-11-16 |
EP1755604B1 (en) | 2009-10-14 |
MXPA06013128A (es) | 2007-04-27 |
WO2005107752A2 (en) | 2005-11-17 |
CN1997369A (zh) | 2007-07-11 |
DE602005017145D1 (de) | 2009-11-26 |
CN1997369B (zh) | 2011-12-21 |
ES2334042T3 (es) | 2010-03-04 |
CA2566398A1 (en) | 2005-11-17 |
AU2005239831A1 (en) | 2005-11-17 |
JP2012254986A (ja) | 2012-12-27 |
RU2006143770A (ru) | 2008-06-20 |
US20070167474A1 (en) | 2007-07-19 |
NO20065551L (no) | 2007-02-05 |
JP2007537198A (ja) | 2007-12-20 |
ATE445401T1 (de) | 2009-10-15 |
EP1755604A2 (en) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200609337B (en) | Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin | |
AP2037A (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
WO2005089753A3 (en) | Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders | |
BR0312934A (pt) | Derivados de 8-hidróxi quinolina | |
MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
GEP20125405B (en) | Amino-heterocyclic compounds | |
WO2005023759A3 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
WO2005080352A3 (en) | Quinazoline derivatives and therapeutic use thereof | |
ATE517882T1 (de) | Chinolinderivate | |
SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
EA017278B9 (ru) | Соединения азаиндазола и способы применения | |
MY147442A (en) | Imidazoquinolines as lipid kinase inhibitors | |
EA200801998A1 (ru) | ПИРИДИН[3,4-b]ПИРАЗИНОНЫ | |
TW200635923A (en) | Tricyclic heterocycles, their manufacture and use as pharmaceutical agents | |
MY137156A (en) | Dual nk1/nk3 derivatives | |
NZ593440A (en) | Aminopyrazole compounds useful for inhibiting chk1 | |
MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. | |
IL191751A0 (en) | Pyrrolo[2,3-c]pyridine derivatives | |
UA96304C2 (xx) | ПОХІДНІ 2-МЕТИЛМОРФОЛІН ПІРИДО-, ПІРАЗО- І ПІРИМІДО-ПІРИМІДИНУ ЯК ІНГІБІТОРИ mTOR[ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА КАК ИНГИБИТОРЫ mTOR | |
TW200732304A (en) | Piperidine derivatives | |
WO2007092157A9 (en) | 7-(1h-imidazol-4-yl) methyl) -5,6,7,8-tetrahydroquinoline | |
TW200635592A (en) | Pyridyl-substituted spiro-hydantoin compounds and use thereof | |
WO2008004100A3 (en) | Therapeutic compounds |